JP2021529766A5 - - Google Patents

Info

Publication number
JP2021529766A5
JP2021529766A5 JP2020573242A JP2020573242A JP2021529766A5 JP 2021529766 A5 JP2021529766 A5 JP 2021529766A5 JP 2020573242 A JP2020573242 A JP 2020573242A JP 2020573242 A JP2020573242 A JP 2020573242A JP 2021529766 A5 JP2021529766 A5 JP 2021529766A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
composition according
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020573242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529766A (ja
JP7513533B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040196 external-priority patent/WO2020010024A1/en
Publication of JP2021529766A publication Critical patent/JP2021529766A/ja
Publication of JP2021529766A5 publication Critical patent/JP2021529766A5/ja
Application granted granted Critical
Publication of JP7513533B2 publication Critical patent/JP7513533B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573242A 2018-07-02 2019-07-01 リポタンパク質aの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療 Active JP7513533B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862693218P 2018-07-02 2018-07-02
US62/693,218 2018-07-02
US201862697353P 2018-07-12 2018-07-12
US62/697,353 2018-07-12
PCT/US2019/040196 WO2020010024A1 (en) 2018-07-02 2019-07-01 Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis

Publications (3)

Publication Number Publication Date
JP2021529766A JP2021529766A (ja) 2021-11-04
JP2021529766A5 true JP2021529766A5 (cg-RX-API-DMAC7.html) 2022-07-11
JP7513533B2 JP7513533B2 (ja) 2024-07-09

Family

ID=69060543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573242A Active JP7513533B2 (ja) 2018-07-02 2019-07-01 リポタンパク質aの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療

Country Status (7)

Country Link
US (1) US20210155682A1 (cg-RX-API-DMAC7.html)
EP (1) EP3817768A4 (cg-RX-API-DMAC7.html)
JP (1) JP7513533B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210056325A (cg-RX-API-DMAC7.html)
CN (1) CN112839672A (cg-RX-API-DMAC7.html)
CA (1) CA3105071A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020010024A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
JP2023523145A (ja) 2020-04-27 2023-06-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア リポ蛋白(a)に対するイソ型非依存性抗体
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2026165210A1 (en) * 2025-01-30 2026-08-06 Abcentra, Llc Treatment regimens for reducing risk of major adverse cardiovascular event

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727102B1 (en) * 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2240156A2 (en) * 2007-12-28 2010-10-20 BioInvent International AB Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
PE20120359A1 (es) * 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
ES2773111T3 (es) * 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
CN114558129A (zh) * 2014-03-17 2022-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Similar Documents

Publication Publication Date Title
JP2020002171A5 (cg-RX-API-DMAC7.html)
JP2017160208A5 (cg-RX-API-DMAC7.html)
JP2023515271A5 (cg-RX-API-DMAC7.html)
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
JP2020500152A5 (cg-RX-API-DMAC7.html)
JP2019523295A5 (cg-RX-API-DMAC7.html)
JP2021530438A5 (cg-RX-API-DMAC7.html)
RU2005127429A (ru) Активная иммунизация для создания антител к растворимому а-бета
JP2013543501A5 (cg-RX-API-DMAC7.html)
JP2014114288A5 (cg-RX-API-DMAC7.html)
JP2013521303A5 (cg-RX-API-DMAC7.html)
JP2024112859A5 (cg-RX-API-DMAC7.html)
JP2021532126A5 (cg-RX-API-DMAC7.html)
JP2020502261A5 (cg-RX-API-DMAC7.html)
JP2020535149A5 (cg-RX-API-DMAC7.html)
JP2021511024A5 (cg-RX-API-DMAC7.html)
CN120677175A (zh) 肌生成抑制蛋白活化的选择性和强效抑制剂
JP2024540226A5 (cg-RX-API-DMAC7.html)
CA3169827A1 (en) Compositions of il-6/il-6r antibodies and methods of use thereof
JP2021523138A5 (cg-RX-API-DMAC7.html)
JP2025505642A5 (cg-RX-API-DMAC7.html)
JP2023506779A5 (cg-RX-API-DMAC7.html)
JP2023534916A5 (cg-RX-API-DMAC7.html)
CA3185105A1 (en) Cd-3 antibodies for the treatment of coronavirus
JP2022520572A (ja) 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のcd38細胞膜分子に対するモノクローナル抗体の組み合わせによるalアミロイドーシスの処置